Sai Life Sciences Expands with New Hyderabad R&D Center

Sai Life Sciences Limited has taken a significant step in boosting its research and development capabilities with the announcement of a new CMC Process R&D Center in Hyderabad, India. The facility, slated for completion by September 2026, aims to double the company's existing R&D capacity.

The new center will introduce specialized capabilities in peptide development, oligo intermediates, formulation development, and early-phase clinical supplies. CEO Krishna Kanumuri emphasized the importance of agility and speed in today's compressed timelines, stating that the center will enhance the company's ability to deliver scientific excellence effectively.

Designed as a green building, the R&D center spans 100,000 sq. ft. with a range of state-of-the-art facilities, including a centralized analytical lab and containment capabilities down to OEL 4. This strategic investment reflects the growing demand for scalable clinical-scale programs and positions Sai Life Sciences as a preferred partner in drug development.